Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenyang Yishen Tongluo Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by the Yunnan Hospital of Traditional Chinese Medicine (also known as the First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine). The decoction is specifically formulated to treat rheumatoid arthritis (RA), particularly cases classified under the TCM syndromes of 'Wind-Cold-Dampness Bi Syndrome' or 'Cold Type' RA. Its therapeutic rationale is based on the principles of warming yang (Wenyang), tonifying the kidney (Yishen), and dredging the collaterals (Tongluo) to alleviate joint pain, swelling, and stiffness. Clinical research is also exploring its efficacy in treating RA-associated osteoporosis, suggesting a potential role in modulating bone metabolism and reducing systemic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wenyang yishen tongluo decoction.